Core Laboratories N.V. beat EPS estimates 88% of the time across 16 reported quarters (14 beats, 2 misses), averaging +20.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.08 | $0.11 | +37.5% | Beat | |
| Q1 FY26 | $0.06 | $0.06 | +0.0% | Beat | |
| Q4 FY25 | $0.20 | $0.21 | +5.0% | Beat | Q4 FY25 call · transcript |
| Q3 FY25 | $0.19 | $0.22 | +15.8% | Beat | |
| Q2 FY25 | $0.18 | $0.19 | +5.6% | Beat | Q2 FY25 call · transcript |
| Q1 FY25 | $0.15 | $0.08 | -46.7% | Miss | |
| Q4 FY24 | $0.21 | $0.23 | +9.5% | Beat | |
| Q2 FY24 | $0.17 | $0.22 | +29.4% | Beat | |
| Q1 FY24 | $0.11 | $0.13 | +18.2% | Beat | |
| Q4 FY23 | $0.14 | $0.19 | +35.7% | Beat | |
| Q3 FY23 | $0.18 | $0.22 | +22.2% | Beat | |
| Q2 FY23 | $0.15 | $0.23 | +53.3% | Beat |
Back to CLB overview · CLB holders · CLB KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.